Baxter International Inc. (BAX - Free Report) recently launched Sharesource 2.0 clinical portal to improve peritoneal dialysis (“PD”) treatment at home. Sharesource 2.0 is a remote patient management platform, providing real-time data which helps take timely treatment decisions.
The latest development fortifies Baxter’s foothold in the global dialysis market.
More on Sharesource 2.0
The new Sharesource 2.0 provides a more comprehensive patient treatment summary to enable faster clinical insights. Notably, a study using Baxter’s HomeChoice Claria with Sharesource found that the platform can achieve time and cost savings for providers and patients by allowing for a more personalized therapy regime and early detection and treatment.
The Sharesource 2.0 is available on Baxter’s Amia and HomeChoice Claria APD systems across Europe, Canada, Latin America and the United States.
For investors’ notice, Baxter had launched the first version of Sharesource in 2016, the telehealth platform to support home dialysis therapy. It is a two-way, cloud-based technology platform that provides recently completed dialysis-related treatment data after each PD session.
Baxter boasts a broad product spectrum which makes it one of the leading players in the renal care space.
Notably, its other products include BICART Cartridge, Cartridge Blood Set, DIACLEAR Ultrafilter, DIASCAN Monitoring System, EXELTRA Dialyzer High-Flux, Single-Use Dialyzers, PD Simple Paks and POLYFLUX 6H Dialyzer. These products enjoy high demand and have been significantly contributing to the company’s top line in the past several quarters.
It is encouraging to note that management at Baxter expects growth of around 2% to 3% at cc in the renal care segment in 2019.
Global Market Insights opines that the world dialysis market is likely to surpass $104 billion by 2024, courtesy to growing R&D activities by renal care bigwigs.
Hence, the latest development has been a well-timed one for Baxter.
We believe positive developments such as these will boost the Zacks Rank #3 (Hold) stock, which has rallied 5.3% compared with the industry’s 6.4% rise, in a year’s time.
A few better-ranked stocks in the broader medical space are DENTSPLY SIRONA (XRAY - Free Report) , Masimo Corporation (MASI - Free Report) ad CONMED Corporation (CNMD - Free Report) , each carrying a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
DENTSPLY’s long-term earnings growth rate is expected at 11.5%.
Masimo’s long-term earnings growth rate is projected at 16.1%.
CONMED’s long-term earnings growth rate is estimated at 13.3%.
The Hottest Tech Mega-Trend of All
Last year, it generated $8 billion in global revenues. By 2020, it's predicted to blast through the roof to $47 billion. Famed investor Mark Cuban says it will produce "the world's first trillionaires," but that should still leave plenty of money for regular investors who make the right trades early.
See Zacks' 3 Best Stocks to Play This Trend >>